BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23996528)

  • 1. SLAT negatively regulates RANKL-induced osteoclast differentiation.
    Youn BU; Kim K; Kim JH; Lee J; Moon JB; Kim I; Park YW; Kim N
    Mol Cells; 2013 Sep; 36(3):252-7. PubMed ID: 23996528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The paired-box homeodomain transcription factor Pax6 binds to the upstream region of the TRAP gene promoter and suppresses receptor activator of NF-κB ligand (RANKL)-induced osteoclast differentiation.
    Kogawa M; Hisatake K; Atkins GJ; Findlay DM; Enoki Y; Sato T; Gray PC; Kanesaki-Yatsuka Y; Anderson PH; Wada S; Kato N; Fukuda A; Katayama S; Tsujimoto M; Yoda T; Suda T; Okazaki Y; Matsumoto M
    J Biol Chem; 2013 Oct; 288(43):31299-312. PubMed ID: 23990468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB.
    Kang MR; Jo SA; Yoon YD; Park KH; Oh SJ; Yun J; Lee CW; Nam KH; Kim Y; Han SB; Yu J; Rho J; Kang JS
    Mar Drugs; 2014 Nov; 12(11):5643-56. PubMed ID: 25421321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The fungal metabolite (+)-terrein abrogates osteoclast differentiation via suppression of the RANKL signaling pathway through NFATc1.
    Nakagawa S; Omori K; Nakayama M; Mandai H; Yamamoto S; Kobayashi H; Sako H; Sakaida K; Yoshimura H; Ishii S; Ibaragi S; Hirai K; Yamashiro K; Yamamoto T; Suga S; Takashiba S
    Int Immunopharmacol; 2020 Jun; 83():106429. PubMed ID: 32222639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carboxypeptidase E is a novel modulator of RANKL-induced osteoclast differentiation.
    Kim HJ; Hong J; Yoon HJ; Yoon YR; Kim SY
    Mol Cells; 2014 Sep; 37(9):685-90. PubMed ID: 25220258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coenzyme q10 regulates osteoclast and osteoblast differentiation.
    Moon HJ; Ko WK; Jung MS; Kim JH; Lee WJ; Park KS; Heo JK; Bang JB; Kwon IK
    J Food Sci; 2013 May; 78(5):H785-891. PubMed ID: 23582186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of matrix metalloproteinase-9 activity by doxycycline ameliorates RANK ligand-induced osteoclast differentiation in vitro and in vivo.
    Franco GC; Kajiya M; Nakanishi T; Ohta K; Rosalen PL; Groppo FC; Ernst CW; Boyesen JL; Bartlett JD; Stashenko P; Taubman MA; Kawai T
    Exp Cell Res; 2011 Jun; 317(10):1454-64. PubMed ID: 21420951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The inhibitory effect of vitamin K on RANKL-induced osteoclast differentiation and bone resorption.
    Wu WJ; Kim MS; Ahn BY
    Food Funct; 2015 Oct; 6(10):3351-8. PubMed ID: 26267519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
    Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
    J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MafB negatively regulates RANKL-mediated osteoclast differentiation.
    Kim K; Kim JH; Lee J; Jin HM; Kook H; Kim KK; Lee SY; Kim N
    Blood; 2007 Apr; 109(8):3253-9. PubMed ID: 17158225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MCP-1-induced human osteoclast-like cells are tartrate-resistant acid phosphatase, NFATc1, and calcitonin receptor-positive but require receptor activator of NFkappaB ligand for bone resorption.
    Kim MS; Day CJ; Selinger CI; Magno CL; Stephens SR; Morrison NA
    J Biol Chem; 2006 Jan; 281(2):1274-85. PubMed ID: 16280328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory mechanism of NFATc1 in RANKL-induced osteoclast activation.
    Song I; Kim JH; Kim K; Jin HM; Youn BU; Kim N
    FEBS Lett; 2009 Jul; 583(14):2435-40. PubMed ID: 19576893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pim-1 regulates RANKL-induced osteoclastogenesis via NF-κB activation and NFATc1 induction.
    Kim K; Kim JH; Youn BU; Jin HM; Kim N
    J Immunol; 2010 Dec; 185(12):7460-6. PubMed ID: 21068407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kalkitoxin Reduces Osteoclast Formation and Resorption and Protects against Inflammatory Bone Loss.
    Li L; Yang M; Shrestha SK; Kim H; Gerwick WH; Soh Y
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33669069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chlorogenic acid inhibits osteoclast differentiation and bone resorption by down-regulation of receptor activator of nuclear factor kappa-B ligand-induced nuclear factor of activated T cells c1 expression.
    Kwak SC; Lee C; Kim JY; Oh HM; So HS; Lee MS; Rho MC; Oh J
    Biol Pharm Bull; 2013; 36(11):1779-86. PubMed ID: 23985829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells.
    Kim JM; Lee JH; Lee GS; Noh EM; Song HK; Gu DR; Kim SC; Lee SH; Kwon KB; Lee YR
    BMC Complement Altern Med; 2017 Mar; 17(1):164. PubMed ID: 28335757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constant hypoxia inhibits osteoclast differentiation and bone resorption by regulating phosphorylation of JNK and IκBα.
    Ma Z; Yu R; Zhao J; Sun L; Jian L; Li C; Liu X
    Inflamm Res; 2019 Feb; 68(2):157-166. PubMed ID: 30604211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
    Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
    Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ganomycin I from Ganoderma lucidum attenuates RANKL-mediated osteoclastogenesis by inhibiting MAPKs and NFATc1.
    Tran PT; Dat NT; Dang NH; Van Cuong P; Lee S; Hwangbo C; Van Minh C; Lee JH
    Phytomedicine; 2019 Mar; 55():1-8. PubMed ID: 30668419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.